辛伐他汀对腹膜透析患者炎症状态的影响

目的探讨辛伐他汀短期治疗对腹膜透析患者炎症因子水平的影响。方法以云南省保山市第二人民医院肾内科48例稳定的腹膜透析患者为研究对象，以20例健康志愿者为对照组；治疗组患者分别于治疗前及辛伐他汀治疗8周后，空腹抽血查血脂，包括：血清总胆固醇脂、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）和甘油三酯；以及肌酸磷酸激酶（CK）和谷草转氨酶（SGOT）；检测炎症指标，血清高敏C反应蛋白（hs—CRP），白介素6（IL-6）和白介素10（IL1-0），对照组进行上述相同的检查，并与对照组基础值进行比较。结果与健康对照组比较，腹膜透析患者存在高血脂和高炎症状态，经过辛伐他汀治疗8周后，腹膜透析患者的血清总胆固醇脂、低密度脂蛋白和甘油三酯明显卜降，而高密度脂蛋白明显上升，结果具有显著意义。炎症因子hs—CRP和IL-6水甲显著降低，与治疗前比较，差异有显著性，P〈0．05和P〈0．05：而抗炎症因子IL-10水平显著升高，P〈0．05。结论辛伐他汀对腹膜透析患者有显著的降血脂和抗炎症作用。

The influence of Simvastatin on inflammation in peritoneal dialysis patients

Objective to explore the influence of short term treatment of Simvastatin oninflammation in peritoneal dialysis patients. Methods Fourty-eight stable peritoneal dialysispatients were enrolled in this study as treated group, and another 20 health volunteers ascontrols. Some serum examinations which included total cholesterol, LDL cholesterol, HDLcholesterol,Triglycerides,creatine kinase(CK), aspartate aminotransferase(AST) and some in-flammatory markers such as high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)and interleukin-10 (IL-10) were performend in the patients before and after 8 weeks treatmentof Simvastatin and inthe cotrols. Results compared with the controls, high lipidemia andinflammatory status existed on peritoneal dialysis patients, but after 8 weeks treatment ofSimvastatin, the total cholesterol, LDL cholesterol and triglycerides declined Significantlyand the HDL cholesterol raised significantly(P <0.05); inflammatory factor such as hs-CRPand IL-6 declined significantly, P <0.05 and P <0.05, respectively; and the anti-inflamma-tory factor IL-10 raised significantly, P<0.05. Conclusion There is significant anti-lipidemicand anti-inflammation effect of Simvastatin in peritoneal dialysis patients.